Status:
RECRUITING
The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement
Lead Sponsor:
Ajou University School of Medicine
Conditions:
Opioid Use
Eligibility:
All Genders
19-60 years
Phase:
NA
Brief Summary
Maxigesic is combined intravenous analgesic of ibuprofen and acetaminphen. The purpose of this study is investigate weather preoperative Maxigesic administration can reduce intraoperative remifentanil...
Detailed Description
Remifentanil is an ultra-short-acting opioid that is useful during surgery because of its fast onset and recovery. However, because of this profile, it is known that the use of high doses of remifenta...
Eligibility Criteria
Inclusion
- Adult patients (19-60 years old) with ASA physical status 1, 2, 3
- Scheduled surgery under general anesthesia
Exclusion
- The patient does not conset
- Pregnancy
- hepatic disorder
- Renal disorder
- Asthma
- Hypersensitivity to the NSAIDs or acetaminophen
- Patients receiving chronic pain therapy
- Drug dependence
- Patients taking psychiatric drugs
- Alcoholics
- History of gastrointestinal ulcer or bleeding
Key Trial Info
Start Date :
August 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06015711
Start Date
August 30 2023
End Date
December 31 2026
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ajou university school of medicine
Suwon, Gyeonggi-do, South Korea, 16499